Check for updates

Cancer Cachexia: ASCO Guideline Rapid Recommendation Update

Eric J. Roeland, MD[1]; Kari Bohlke, ScD[2]; Vickie E. Baracos, PhD[3]; Thomas J. Smith, MD[4]; and Charles L. Loprinzi, MD[5]; for the Cancer Cachexia Expert Panel

DOI https://doi.org/10.1200/JCO.23.01280

ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options. See the Appendix for disclaimers and other important information (Appendix 1 and Appendix 2, online only).

ACCOMPANYING CONTENT

Article, July 20, 2020 issue on page 2438

Appendix

Accepted June 16, 2023
Published July 12, 2023

Evidence-Based Medicine Committee approval: June 13, 2023

J Clin Oncol 41:4178-4179

© 2023 by American Society of Clinical Oncology

View Online Article

Downloaded from ascopubs.org by 73.89.6.182 on February 12, 2025 from 073.089.006.182
Copyright © 2025 American Society of Clinical Oncology. All rights reserved.

BACKGROUND

In 2020, ASCO published a guideline on the management of cancer cachexia in adults with advanced cancer.[1] Evidence was insufficient to strongly endorse any pharmacologic agent, but recommendations supported clinicians in offering a short-term trial of a progesterone analog or corticosteroid to patients experiencing loss of weight and/or appetite. The Expert Panel discussed a potential role for olanzapine but concluded that the evidence was insufficient for a recommendation. The publication of a 2023 randomized controlled trial (RCT) of olanzapine prompted the Expert Panel to revisit this topic.[2]

METHODS

An updated literature search identified RCTs published from October 1, 2019, to April 19, 2023. Five addressed pharmacologic interventions.[2-6] The Expert Panel reviewed the evidence and approved the revised recommendations. The quality of evidence and strength of recommendation were classified using the methods of the 2020 guideline.[1]

EVIDENCE REVIEW

Investigators evaluated olanzapine's impact on chemotherapy-related anorexia in a double-blind, placebo-controlled RCT that enrolled 124 adults (median age 55 years) with locally advanced or metastatic gastric, hepatopancreaticobiliary, or lung cancer. Starting with chemotherapy initiation, patients received olanzapine (2.5 mg once a day) or placebo for 12 weeks. During the 4 days after chemotherapy, all patients received olanzapine 5 mg once a day and dexamethasone as antiemetics.[2] Weight gain > 5% occurred in 60% of patients in the olanzapine arm versus 9% in the placebo arm ($P < .001$). Patients receiving olanzapine also experienced improved appetite. Grade ≥3 chemotherapy toxicity was less common with olanzapine (12%, *v* 37% with placebo, $P = .002$). Grade ≥3 toxicity attributed to the trial drug occurred in one patient in the olanzapine arm and two patients in the placebo arm.

Additional data from a 2010 trial of 80 patients with advanced GI or lung cancers showed that adding olanzapine to megestrol acetate resulted in significantly more weight gain than megestrol acetate alone. The effect on appetite was even more pronounced.[7] Finally, a pilot RCT supported olanzapine's impact on appetite over 1 week in patients with advanced cancer and nausea unrelated to chemotherapy (appetite numeric rating score was 2/10 with placebo *v* 7/10 with olanzapine 5 mg once daily).[6] This trial included 30 patients with breast, head and neck, gynecologic, genitourinary, GI, or lung cancer. Patients in these latter two trials did not receive

concurrent chemotherapy. Currently, it is unclear whether olanzapine improves strength or body composition in patients with cancer-associated anorexia.

In the opinion of the Expert Panel, the other identified trials[3-5] did not change prior pharmacologic intervention guideline recommendations. Notably, mirtazapine 15 mg once nightly was no better than placebo for cancer-related anorexia and cachexia,[4] which aligns with the 2020 guideline recommendations.

UPDATED RECOMMENDATIONS

Note: There are currently no FDA-approved medications to treat cancer cachexia.

Recommendation 2.1

For adults with advanced cancer, clinicians may offer low-dose olanzapine once daily to improve weight gain and appetite (Type: Evidence based; Evidence quality: Intermediate; Strength of recommendation: Moderate).

Qualifying statement: The majority of evidence for Recommendation 2.1 involves patients with lung or GI cancer, and the largest study enrolled patients receiving cytotoxic chemotherapy.

Recommendation 2.2

For patients who cannot tolerate low-dose olanzapine, clinicians may offer a short-term trial of a progesterone analog or a corticosteroid to those experiencing loss of weight and/or appetite (Type: Evidence based; Evidence quality: Intermediate; Strength of recommendation: Moderate).

A table of all guideline recommendations is available at www.asco.org/supportive-care-guidelines.

Downloaded from ascopubs.org by 73.89.6.182 on February 12, 2025 from 073.089.006.182
Copyright © 2025 American Society of Clinical Oncology. All rights reserved.

AFFILIATIONS

[1]Oregon Health and Science University, Knight Cancer Institute, Portland, OR
[2]American Society of Clinical Oncology, Alexandria, VA
[3]University of Alberta, Edmonton, Alberta, Canada
[4]Johns Hopkins Medicine, Baltimore, MD
[5]Mayo Clinic, Rochester, MN

CORRESPONDING AUTHOR

American Society of Clinical Oncology, 2318 Mill Rd, Suite 800, Alexandria, VA 22314; e-mail: guidelines@asco.org.

EDITOR'S NOTE

This ASCO Clinical Practice Guideline Recommendation Update provides a recommendation update, with a review and analysis of the relevant literature for the recommendation. Additional information, including links to patient information at www.cancer.net, is available at www.asco.org/supportive-care-guidelines

EQUAL CONTRIBUTION

E.J.R. and C.L.L. were Expert Panel cochairs.

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the authors are available with this article at DOI https://doi.org/10.1200/JCO.23.01280.

AUTHOR CONTRIBUTIONS

Conception and design: All authors
Collection and assembly of data: Kari Bohlke, Thomas J. Smith, Charles L. Loprinzi
Data analysis and interpretation: All authors
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors

ACKNOWLEDGMENT

The authors wish to thank K. Scott Baker, MD, MS; Elizabeth Shaw, NP; and the ASCO Evidence Based Medicine Committee for their thoughtful reviews and insightful comments on this guideline update. Members of the Cancer Cachexia Guideline Panel are listed in Appendix 3 (online only).

REFERENCES

1. Roeland EJ, Bohlke K, Baracos VE, et al: Management of cancer cachexia: ASCO guideline. J Clin Oncol 38:2438-2453, 2020
2. Sandhya L, Devi Sreenivasan N, Goenka L, et al: Randomized double-blind placebo-controlled study of olanzapine for chemotherapy-related anorexia in patients with locally advanced or metastatic gastric, hepatopancreaticobiliary, and lung cancer. J Clin Oncol 41:2617-2627, 2023
3. Currow DC, Glare P, Louw S, et al: A randomised, double blind, placebo-controlled trial of megestrol acetate or dexamethasone in treating symptomatic anorexia in people with advanced cancer. Sci Rep 11:2421, 2021
4. Hunter CN, Abdel-Aal HH, Elsherief WA, et al: Mirtazapine in cancer-associated anorexia and cachexia: A double-blind placebo-controlled randomized trial. J Pain Symptom Manage 62:1207-1215, 2021
5. Naito T, Uchino J, Kojima T, et al: A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index. Cancer 128:2025-2035, 2022
6. Navari RM, Pywell CM, Le-Rademacher JG, et al: Olanzapine for the treatment of advanced cancer-related chronic nausea and/or vomiting: A randomized pilot trial. JAMA Oncol 6:895-899, 2020
7. Navari RM, Brenner MC: Treatment of cancer-related anorexia with olanzapine and megestrol acetate: A randomized trial. Support Care Cancer 18:951-956, 2010

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Cancer Cachexia: ASCO Guideline Rapid Recommendation Update

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Eric J. Roeland
Consulting or Advisory Role: Napo Pharmaceuticals, Helsinn Therapeutics, Byomass, Veloxis, PRA Health, Actimed Therapeutics, Takeda, Meter Health
Travel, Accommodations, Expenses: Pfizer

Vickie E. Baracos
Honoraria: Pfizer, Nestle health science
Consulting or Advisory Role: Nestle Health Science, Pfizer
Research Funding: Baxter

Thomas J. Smith
Employment: UpToDate
Honoraria: Athenex, Association of Community Cancer Centers
Patents, Royalties, Other Intellectual Property: Royalties from Oxford Textbook of Cancer Communication, co-editor
Open Payments Link: https://openpaymentsdata.cms.gov/physician/202382

Charles L. Loprinzi
Consulting or Advisory Role: Metys Pharmaceuticals, Disarm Therapeutics, OnQuality Pharmaceuticals, NKMax, Mitsubishi Tanabe Pharma, Veloxis, Metys Pharmaceuticals, Hengrui Pharmaceutical, Osmol Therapeutics, Grunenthal, Neuropathix, Denali Therapeutics, Bexion, Veloxis, Vevro, Galendia, Hengrui Pharmaceutical, Neuropathix, Neuropathix, Denali Therapeutics, Bexion, Bexion, Bexion, Genentech
Research Funding: Bristol Myers Squibb (Inst)

No other potential conflicts of interest were reported.

Downloaded from ascopubs.org by 73.89.6.182 on February 12, 2025 from 073.089.006.182
Copyright © 2025 American Society of Clinical Oncology. All rights reserved.

© 2023 by American Society of Clinical Oncology

APPENDIX 1. GUIDELINE DISCLAIMER

The Clinical Practice Guidelines and other guidance published herein are provided by ASCO to assist providers in clinical decision making. The information herein should not be relied upon as being complete or accurate, nor should it be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. With the rapid development of scientific knowledge, new evidence may emerge between the time information is developed and when it is published or read. The information is not continually updated and may not reflect the most recent evidence. The information addresses only the topics specifically identified therein and is not applicable to other interventions, diseases, or stages of diseases. This information does not mandate any particular course of medical care. Further, the information is not intended to substitute for the independent professional judgment of the treating provider, as the information does not account for individual variation among patients. Recommendations specify the level of confidence that the recommendation reflects the net effect of a given course of action. The use of words like "must," "must not," "should," and "should not" indicate that a course of action is recommended or not recommended for either most or many patients, but there is latitude for the treating physician to select other courses of action in individual cases. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the information is voluntary. ASCO does not endorse third-party drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions. Any use of a brand or trade name is for identification purposes only. ASCO provides this information on an "as is" basis and makes no warranty, express or implied, regarding the information. ASCO specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information, or for any errors or omissions.

APPENDIX 2. GUIDELINE AND CONFLICTS OF INTEREST

The Expert Panel was assembled in accordance with ASCO's Conflict of Interest Policy Implementation for Clinical Practice Guidelines ("Policy," found at https://www.asco.org/guideline-methodology). All members of the Expert Panel completed ASCO's disclosure form, which requires disclosure of financial and other interests, including relationships with commercial entities that are reasonably likely to experience direct regulatory or commercial impact as a result of promulgation of the guideline. Categories for disclosure include employment; leadership; stock or other ownership; honoraria, consulting or advisory role; speaker's bureau; research funding; patents, royalties, and other intellectual property; expert testimony; travel, accommodations, and expenses; and other relationships. In accordance with the Policy, the majority of the members of the Expert Panel did not disclose any relationships constituting a conflict under the Policy.

APPENDIX 3. CANCER CACHEXIA GUIDELINE PANEL

The following are members of the Cancer Cachexia Guideline Panel: Eric J. Roeland, MD; Vickie E. Baracos, PhD; Eduardo Bruera, MD; Egidio del Fabbro, MD; Suzanne Dixon, MPH, MS, RD; Marie Fallon, MD; Jørn Herrstedt, MD, DMSci; Harold Lau, MD; Mary Platek, PhD, MS, RD; Hope S. Rugo, MD; Thomas J. Smith, MD; Winston Tan, MD; Charles L. Loprinzi, MD.

Downloaded from ascopubs.org by 73.89.6.182 on February 12, 2025 from 073.089.006.182
Copyright © 2025 American Society of Clinical Oncology. All rights reserved.